Phio Pharmaceuticals Corp. (PHIO) · Nov 20, 2026 · Delisting
Nasdaq deficiency notice — Below $1 for 30 consecutive business days; cure deadline May 17, 2027
Phio Pharmaceuticals received a Nasdaq deficiency notice, giving it until May 17, 2027 to restore its $1 bid price while PH-762 advances.
Phio is a cash-burning clinical-stage biotech trying to move its lead cancer candidate, PH-762, from a completed Phase 1b study toward a planned Phase 2b trial in early 2027; the company had $10.6 million in cash at September 30, 2026, down from $21.0 million at year-end 2025.
The filing adds a formal Nasdaq deficiency, not an immediate delisting. Phio says its stock closed below the required $1.00 bid price for 30 straight business days, but the notice does not immediately affect listing or trading. 〔0〕
The company now has a defined six-month window to fix the problem. Nasdaq gives Phio until May 17, 2027 to regain compliance, requiring a closing bid of at least $1.00 for 10 consecutive business days. 〔1〕
This is a modest setback to the operating story because the timing overlaps with the next major development phase. Phio is preparing PH-762 manufacturing and regulatory work for a planned Phase 2b start in the first quarter of 2027, so the cure period covers the exact window in which the company needs market access and financing flexibility. The deficiency itself was partly telegraphed in the latest 10-Q, which already disclosed 21 consecutive days below the minimum bid price and noted that Phio has previously used reverse splits to regain compliance.
Bottom line: The notice does not interrupt trading today, but it adds a real capital-markets problem to an already cash-constrained clinical transition. It matters less as a new shock than as a deadline now hanging over PH-762’s planned Phase 2b advance.
10-session $1 bid-price test before May 17, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!